Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May;75(5):1340.
doi: 10.1002/hep.32353. Epub 2022 Feb 10.

Letter to the editor: Circulating thrombospondin-2 as a biomarker in patients with NAFLD with and without diabetes-Are we convinced yet?

Chi Ho Lee  1   2 , David T W Lui  1 , Karen S L Lam  1   2
Affiliations
Comment

Letter to the editor: Circulating thrombospondin-2 as a biomarker in patients with NAFLD with and without diabetes-Are we convinced yet?

Chi Ho Lee et al. Hepatology. 2022 May.
No abstract available

PubMed Disclaimer

Comment in

  • Reply.
    Kodama T, Takehara T. Kodama T, et al. Hepatology. 2022 May;75(5):1341. doi: 10.1002/hep.32351. Epub 2022 Feb 11. Hepatology. 2022. PMID: 35066910 No abstract available.

Comment on

References

    1. Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, et al. Transcriptomics identify thrombospondin‐2 as a biomarker for NASH and advanced liver fibrosis. Hepatology. 2021;74:2452–66.
    1. Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, et al. Metabolic risk factors and incident advanced liver disease in non‐alcoholic fatty liver disease (NAFLD): a systematic review and meta‐analysis of population‐based observational studies. PLoS Medicine. 2020;17:e1003100.
    1. Lee CH, Seto WK, Lui DT, Fong CH‐Y, Wan HY, Cheung CY‐Y, et al. Circulating thrombospondin‐2 as a novel fibrosis biomarker of nonalcoholic fatty liver disease in type 2 diabetes. Diabetes Care. 2021;44(9):2089–97.
    1. Bril F, McPhaul MJ, Caulfield MP, Clark VC, Soldevilla‐Pico C, Firpi‐Morell RJ, et al. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes. Diabetes Care. 2020;43:290–7.
    1. Kunkemoeller B, Bancroft T, Xing H, Morris AH, Luciano AK, Wu J, et al. Elevated thrombospondin‐2 contributes to delayed wound healing in diabetes. Diabetes. 2019;68(10):2016–23.